Lava Therapeutics B.V. is a biopharmaceutical company specializing in immuno-oncology therapies. The company is a recent spin-out of the VU University Medical Center (VUmc) in Amsterdam, the Netherlands.
Lava Therapeutics´ differentiated technology platform is focusing on first-in-class bispecific antibodies, which engage and activate gamma-delta () T-cells. Gamma-delta T-cells are a promising subclass of T-cells, which have been shown to be positively correlated with overall survival of cancer patients.
Lava Therapeutics raised €16M in financing led by Gilde Healthcare to further develop its bispecific T-cell engager platform, broaden its pipeline and to develop a lead candidate for clinical testing.